Day: April 9, 2021

Steinhausen, April 9, 2021 – Schweiter Technologies is strengthening its 3A Composites core materials business by a PET foam production extension in Poland and has simultaneously signed and closed an agreement to acquire 40% of JMB Wind Engineering (“JMB”). JMB (www.jmbwind.com), based in Goleniów, Poland, is a leading company in core materials kit design and production, mainly for wind turbines, with operations in Poland and Portugal. After the successful start of a PET production line in China in 2020, to expand the capacities in Europe another satellite PET production site is planned for at JMB in Poland, which offers ideal production facilities and logistics. JMB will continue to operate as a stand-alone entity, with the existing management team continuing to run the business from its bases in Poland and Portugal. The minority stake...

Steinhausen, 9. April 2021 – Schweiter Technologies stärkt das 3A Composites Kernmaterial-Geschäft durch eine PET-Schaum Produktionserweiterung in Polen und hat eine Vereinbarung zum Erwerb von 40% der Anteile von JMB Wind Engineering („JMB“) unterzeichnet und gleichzeitig vollzogen. JMB (www.jmbwind.com) mit Sitz in Goleniów, Polen, ist ein führendes Unternehmen in der Entwicklung und Produktion von Kernmaterial-Kits schwergewichtig für Windkraftanlagen, mit Niederlassungen in Polen und Portugal. Nach der erfolgreichen Inbetriebnahme einer PET-Produktionslinie in China im Jahr 2020 ist zum Ausbau der Kapazitäten in Europa bei JMB in Polen ein weiterer PET-Produktionsstandort geplant, der ideale Produktionsmöglichkeiten und Logistikvorteile bietet. JMB wird weiterhin als eigenständige Gesellschaft operieren und das bestehende Managementteam...

VANCOUVER, British Columbia, April 09, 2021 (GLOBE NEWSWIRE) — In a release issued under the same headline on Wednesday April 7, 2021 by Ultra Resources Inc. (TSX-V: ULT), please note that the finders fees have been corrected to $66,322 cash and 602,928 finders warrants. The corrected release follows: Ultra Resources Inc. (TSX-V: ULT) (“Ultra Resources” or the “Company”) is pleased to announce that it has closed a non-brokered private placement of 9,438,250 units at $0.11 per unit for total gross proceeds of $1,038,208. Each Unit is comprised of one common share and one-half non-transferable common share purchase warrant (“Warrant”). Each whole Warrant will entitle the holder to purchase an additional common share of the Company at an exercise price of $0.20 per share for a period of one year from closing of the private...

Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2Early clinical results are consistent with preclinical studies and suggest THOR-707 (SAR444245) may promote an anti-tumor immune response without alpha-mediated side effects, both alone and in combination with anti-PD-1  THOR-707, a precisely PEGylated, engineered version of IL-2 built on Sanofi’s Synthorin™ technology platform, is being studied in a trial of adults with advanced or metastatic solid tumorsPARIS – April 9, 2021 – Interim data from a first-in-human trial evaluating the safety, therapeutic activity and maximum tolerable dose of THOR-707 (SAR444245), a highly differentiated not-alpha interleukin-2 (IL-2) candidate, as a monotherapy and in combination with anti-PD-1, will be presented Saturday, April...

Des données cliniques intermédiaires de dernière minute valident le profil « non-alpha » de THOR-707 (SAR444245), nouvelle IL-2 expérimentale de SanofiLes résultats cliniques précoces confortent ceux des études précliniques et donnent à penser que THOR-707 (SAR444245), en monothérapie ou en association avec un anti-PD-1, pourrait induire une réponse immunitaire antitumorale, sans les effets secondaires médiés par la chaîne alpha. THOR-707, une version modifiée d’IL-2, PEGylée avec précision, développé avec la plateforme technologique Synthorin™ de Sanofi, fait l’objet d’essais cliniques chez des adultes porteurs de tumeurs solides au stade avancé ou métastatiquesPARIS – Le 9 avril 2021 – Les données intermédiaires d’un premier essai chez l’homme évaluant l’innocuité, l’activité thérapeutique et la dose maximale...

BEDFORD, Mass., April 08, 2021 (GLOBE NEWSWIRE) — Progress Software Corporation (NASDAQ: PRGS) (“Progress”) today announced the pricing of its private offering of $325.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2026 (the “Notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Progress also granted the initial purchasers of the Notes an option to purchase up to an additional $50.0 million aggregate principal amount of the Notes, for settlement within a 13-day period beginning on, and including, the first date on which the Notes are issued. The aggregate principal amount of the offering was increased from the previously announced offering size of $300.0 million (or $345.0 million if the initial...

NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) — Magic MergeCo, Inc. (the “Purchaser”), an entity controlled by funds (the “Apollo Funds”) managed by affiliates of Apollo Global Management, Inc. (NYSE: APO) (together with its consolidated subsidiaries, “Apollo”), a leading global alternative investment manager, and The Michaels Companies, Inc. (“Michaels”) (Nasdaq: MIK) today announced an agreement to extend the offering period of the previously commenced cash tender offer by the Purchaser to purchase all of the issued and outstanding shares of common stock of Michaels to 5:00 P.M., New York City time, on April 14, 2021, unless further extended. The tender offer was previously scheduled to expire one minute after 11:59 P.M., New York City time, on April 12, 2021. Computershare Trust Company, N.A., the depositary for the tender offer,...

BASEL, Switzerland, April 08, 2021 (GLOBE NEWSWIRE) — VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need, today announced the pricing of its initial public offering of 7,500,000 ordinary shares at a public offering price of $17.00 per share. The gross proceeds to Vectiv, before deducting underwriting discounts and commissions and offering expenses, are expected to be $127.5 million. All of the ordinary shares are being offered by Vectiv. In addition, Vectiv has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 ordinary shares at the initial public offering price, less the underwriting...

SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $15.00 per share, for total gross proceeds of approximately $93.8 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares are being offered by Reneo. The shares are expected to begin trading on the Nasdaq Global Market on April 9, 2021 under the symbol “RPHM.” In addition, Reneo has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the public offering price less underwriting...

New York, New York, April 08, 2021 (GLOBE NEWSWIRE) — Global SPAC Partners Co. (“Global” or the “Company”) (NASDAQ: GLSPU) announced today that it priced its initial public offering of 16,000,000 units, at $10.00 per unit. The units will be listed on the NASDAQ Capital Market (“NASDAQ”) and will begin trading tomorrow, April 9, 2021, under the ticker symbol “GLSPU.” Each unit consists of one subunit and one-half of a redeemable warrant.  Each subunit consists of one Class A ordinary share and one-quarter of a redeemable warrant. Each full warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the subunits and warrants are expected to be listed on NASDAQ under the symbols “GLSPT” and “GLSPW,” respectively.  Assuming...